13th Edition of International Conference on Neurology and Brain Disorders
October 19-21, 2026
Stroke Diagnosis and Management
Stroke diagnosis and management encompasses a multidisciplinary approach aimed at improving patient survival and recovery. The initial diagnosis involves a combination of clinical evaluation and imaging tools, such as diffusion-weighted MRI, to determine the location and extent of brain damage. Timely treatment, including intravenous thrombolysis and mechanical thrombectomy, is crucial for minimizing brain injury and improving neurological outcomes. In the post-stroke phase, rehabilitation is vital for maximizing recovery, with specialized therapies addressing motor, sensory, and cognitive impairments. Ongoing research into neuroplasticity, brain stimulation techniques, and neuroprotective drugs is helping to optimize stroke management and open new pathways for enhancing patient recovery long after the event.
Ken Ware
NeuroPhysics Therapy Institute and Research Centre, Australia
Yong Xiao Wang
Albany Medical College, United States
Joe Sam Robinson
Mercer University, United States
Daniel Curry
Texas Children’s Hospital, United States
Steven Benvenisti
Davis, Saperstein Salomon, PC, United States
Andrzej Stanislaw Cieplak
Independent researcher, United States
Younok Dumortier Shin
OnusBio, United StatesSubmit your abstract Today
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States